TimothyPardeeTimothy S. Pardee MD, PhD36.08959100000000-80.268599000000001000Pardee, TimothyS.Assistant Professorprns:coAuthorOfcoauthor ofprns:endDateend dateFaculty Rankprns:fullNamefull nameprns:grantAwardedBygrant awarded byprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:principalInvestigatorNameprincipal investigator nameprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:startDatestart dateprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressAgreementvivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentGrantvivo:hasResearchArearesearch areasvivo:hasResearcherRoleresearch activitiesvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:middleNamemiddle name or initialvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleResearcher Rolevivo:researcherRoleOfresearcher role ofRolevivo:roleContributesTocontributes tovivo:sponsorAwardIdsponsor award idURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD009369Disorders1875960.625447NeoplasmsAuthorship 3870612Authorship 402691Authorship 404363Authorship 405405Authorship 406151Authorship 40937424149914Tawfik B, Sliesoraitis S, Lyerly S, Klepin HD, Lawrence J, Isom S, Ellis LR, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee TAnnals of hematologyTawfik B, Sliesoraitis S, Lyerly S, Klepin HD, Lawrence J, Isom S, Ellis LR, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee T. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Ann Hematol. 2014 Jan; 93(1):47-55.Ann Hematol2013-10-23T00:00:002013Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML).24961587Pardee TS, Stadelman K, Jennings-Gee J, Caudell DL, Gmeiner WHOncotargetPardee TS, Stadelman K, Jennings-Gee J, Caudell DL, Gmeiner WH. The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells. Oncotarget. 2014 Jun 30; 5(12):4170-9.Oncotarget2014-06-30T00:00:002014The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells.25071138Klepin HD, Rao AV, Pardee TSJournal of clinical oncology : official journal of the American Society of Clinical OncologyKlepin HD, Rao AV, Pardee TS. Acute myeloid leukemia and myelodysplastic syndromes in older adults. J Clin Oncol. 2014 Aug 20; 32(24):2541-52.J Clin Oncol2014-08-20T00:00:002014Acute myeloid leukemia and myelodysplastic syndromes in older adults.25127690Elliot K, Tooze JA, Geller R, Powell BL, Pardee TS, Ritchie E, Kennedy L, Callahan KE, Klepin HDLeukemia researchElliot K, Tooze JA, Geller R, Powell BL, Pardee TS, Ritchie E, Kennedy L, Callahan KE, Klepin HD. The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML). Leuk Res. 2014 Oct; 38(10):1184-90.Leuk Res2014-07-07T00:00:002014The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML).25165100Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BLClinical cancer research : an official journal of the American Association for Cancer ResearchPardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL. A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Clin Cancer Res. 2014 Oct 15; 20(20):5255-64.Clin Cancer Res2014-08-27T00:00:002014A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies.25402485Cook GJ, Caudell DL, Elford HL, Pardee TSPloS oneCook GJ, Caudell DL, Elford HL, Pardee TS. The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML. PLoS One. 2014; 9(11):e112619.PLoS One2014-11-17T00:00:002014The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML.AnesthesiologyCancer BiologyDermatologyWake Forest School of Medicine5.421750.0187745229research areas2.172240.032021427coauthor of98.633910.82749similar to1134selected publicationsBarbaraYozaBarbara K. Yoza PhD36.08959100000000-80.26859900000000113Yoza, BarbaraProfessorGiuseppeOrlandoGiuseppe Orlando MD, PhD36.08959100000000-80.268599000000001226Orlando, GiuseppeAssociate ProfessorDavidCaudellDavid L. Caudell DVM, PhD36.08943500000000-80.268632000000001400Caudell, DavidAssociate ProfessorAlanFarneyAlan C. Farney MD36.08959100000000-80.2685990000000022Farney, AlanProfessorEdwardLevineEdward A. Levine MD36.08959100000000-80.26859900000000273Levine, EdwardProfessorAnthonyAtalaAnthony Atala MD36.08943500000000-80.268632000000003Atala, AnthonyProfessorHeidiKlepinHeidi D. Klepin MD, MS36.08919100000000-80.26677800000000343Klepin, HeidiProfessorLeslieEllisLeslie R. Ellis MD36.09103700000000-80.26909600000000590Ellis, LeslieProfessorWilliamGmeinerWilliam H. Gmeiner PhD36.09032400000000-80.2664910000000080Gmeiner, WilliamProfessorStevenFeldmanSteven R. Feldman MD, PhD36.08959100000000-80.26859900000000884Feldman, StevenProfessorBayardPowellBayard L. Powell MD36.08919100000000-80.2667780000000099Powell, BayardProfessorAuthorship 413534Authorship 41391325510486Gmeiner WH, Jennings-Gee J, Stuart CH, Pardee TSLeukemia researchGmeiner WH, Jennings-Gee J, Stuart CH, Pardee TS. Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway. Leuk Res. 2015 Feb; 39(2):229-35.Leuk Res2014-11-29T00:00:002014Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway.25563333Pang CS, Pettenati MJ, Pardee TSJournal of clinical pathologyPang CS, Pettenati MJ, Pardee TS. Clinicopathological analysis of near-tetraploidy/tetraploidy acute myeloid leukaemia. J Clin Pathol. 2015 Mar; 68(3):236-40.J Clin Pathol2015-01-06T00:00:002015Clinicopathological analysis of near-tetraploidy/tetraploidy acute myeloid leukaemia.Authorship 463811126154683Ahmed T, Holwerda S, Klepin HD, Isom S, Ellis LR, Lyerly S, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee TSLeukemia researchAhmed T, Holwerda S, Klepin HD, Isom S, Ellis LR, Lyerly S, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee TS. High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly. Leuk Res. 2015 Sep; 39(9):945-9.Leuk Res2015-06-01T00:00:002015High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly.Authorship 483043Authorship 48523226829896Alexander P, Kucera G, Pardee TSCritical reviews in oncology/hematologyAlexander P, Kucera G, Pardee TS. Improving nucleoside analogs via lipid conjugation: Is fatter any better? Crit Rev Oncol Hematol. 2016 Apr; 100:46-56.Crit Rev Oncol Hematol2016-01-21T00:00:002016Improving nucleoside analogs via lipid conjugation: Is fatter any better?26527394Tawfik B, Pardee TS, Isom S, Sliesoraitis S, Winter A, Lawrence J, Powell BL, Klepin HDJournal of geriatric oncologyTawfik B, Pardee TS, Isom S, Sliesoraitis S, Winter A, Lawrence J, Powell BL, Klepin HD. Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML). J Geriatr Oncol. 2016 Jan; 7(1):24-31.J Geriatr Oncol2015-10-30T00:00:002015Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML).Authorship 49707527279153Gmeiner WH, Debinski W, Milligan C, Caudell D, Pardee TSFuture oncology (London, England)Gmeiner WH, Debinski W, Milligan C, Caudell D, Pardee TS. The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence. Future Oncol. 2016 Sep; 12(17):2009-20.Future Oncol2016-06-09T00:00:002016The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence.MatthewLisiMatthew T. Lisi MD36.08959100000000-80.268599000000001981Lisi, MatthewAssistant ProfessorAuthorship 50507227732654Lycan TW, Pardee TS, Petty WJ, Bonomi M, Alistar A, Lamar ZS, Isom S, Chan MD, Miller AA, Ruiz JPloS oneLycan TW, Pardee TS, Petty WJ, Bonomi M, Alistar A, Lamar ZS, Isom S, Chan MD, Miller AA, Ruiz J. A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma. PLoS One. 2016; 11(10):e0164244.PLoS One2016-10-12T00:00:002016A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma.Authorship 51672327627675Klepin HD, Tooze JA, Pardee TS, Ellis LR, Berenzon D, Mihalko SL, Danhauer SC, Rao AV, Wildes TM, Williamson JD, Powell BL, Kritchevsky SBJournal of the American Geriatrics SocietyKlepin HD, Tooze JA, Pardee TS, Ellis LR, Berenzon D, Mihalko SL, Danhauer SC, Rao AV, Wildes TM, Williamson JD, Powell BL, Kritchevsky SB. Effect of Intensive Chemotherapy on Physical, Cognitive, and Emotional Health of Older Adults with Acute Myeloid Leukemia. J Am Geriatr Soc. 2016 10; 64(10):1988-1995.J Am Geriatr Soc2016-09-14T00:00:002016Effect of Intensive Chemotherapy on Physical, Cognitive, and Emotional Health of Older Adults with Acute Myeloid Leukemia.27881872Rodman C, Almeida-Porada G, George SK, Moon J, Soker S, Pardee T, Beaty M, Guida P, Sajuthi SP, Langefeld CD, Walker SJ, Wilson PF, Porada CDLeukemiaRodman C, Almeida-Porada G, George SK, Moon J, Soker S, Pardee T, Beaty M, Guida P, Sajuthi SP, Langefeld CD, Walker SJ, Wilson PF, Porada CD. In vitro and in vivo assessment of direct effects of simulated solar and galactic cosmic radiation on human hematopoietic stem/progenitor cells. Leukemia. 2017 06; 31(6):1398-1407.Leukemia2016-11-24T00:00:002016In vitro and in vivo assessment of direct effects of simulated solar and galactic cosmic radiation on human hematopoietic stem/progenitor cells.2021-04-30NIHPARDEE, TIMOTHY SEBASTIAN2016-05-01Determining the Role of Metabolism in Resistance in Acute Myeloid LeukemiaR01CA1979912017-06-30NIHPARDEE, TIMOTHY SEBASTIAN2012-07-09Metabolic contribution to cell viability and therapy resistance in the acuteK08CA169809Principal InvestigatorPrincipal InvestigatorAuthorship 543736Authorship 543742028495639Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L, Hawkins G, Jin G, Zhang W, Pasche BThe Lancet. OncologyAlistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L, Hawkins G, Jin G, Zhang W, Pasche B. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2017 06; 18(6):770-778.Lancet Oncol2017-05-08T00:00:002017Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.Authorship 55046528644853Alexander PM, Caudell DL, Kucera GL, Pladna KM, Pardee TSPloS oneAlexander PM, Caudell DL, Kucera GL, Pladna KM, Pardee TS. The novel phospholipid mimetic KPC34 is highly active against preclinical models of Philadelphia chromosome positive acute lymphoblastic leukemia. PLoS One. 2017; 12(6):e0179798.PLoS One2017-06-23T00:00:002017The novel phospholipid mimetic KPC34 is highly active against preclinical models of Philadelphia chromosome positive acute lymphoblastic leukemia.Authorship 558481128985622Ahmed T, Koch AL, Isom S, Klepin HD, Bishop JM, Ellis LR, Berenzon D, Howard D, Lyerly S, Powell BL, Pardee TSLeukemia researchAhmed T, Koch AL, Isom S, Klepin HD, Bishop JM, Ellis LR, Berenzon D, Howard D, Lyerly S, Powell BL, Pardee TS. Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit. Leuk Res. 2017 11; 62:51-55.Leuk Res2017-09-27T00:00:002017Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit.29437791Pardee TS, Anderson RG, Pladna KM, Isom S, Ghiraldeli LP, Miller LD, Chou JW, Jin G, Zhang W, Ellis LR, Berenzon D, Howard DS, Hurd DD, Manuel M, Dralle S, Lyerly S, Powell BLClinical cancer research : an official journal of the American Association for Cancer ResearchPardee TS, Anderson RG, Pladna KM, Isom S, Ghiraldeli LP, Miller LD, Chou JW, Jin G, Zhang W, Ellis LR, Berenzon D, Howard DS, Hurd DD, Manuel M, Dralle S, Lyerly S, Powell BL. A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Clin Cancer Res. 2018 05 01; 24(9):2060-2073.Clin Cancer Res2018-02-06T00:00:002018A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia.Authorship 589083Authorship 60200129807044Anderson RG, Ghiraldeli LP, Pardee TSBiochimica et biophysica acta. Reviews on cancerAnderson RG, Ghiraldeli LP, Pardee TS. Mitochondria in cancer metabolism, an organelle whose time has come? Biochim Biophys Acta Rev Cancer. 2018 08; 1870(1):96-102.Biochim Biophys Acta Rev Cancer2018-05-26T00:00:002018Mitochondria in cancer metabolism, an organelle whose time has come?Authorship 6417512Authorship 660113Authorship 66469830773463Lin KH, Xie A, Rutter JC, Ahn YR, Lloyd-Cowden JM, Nichols AG, Soderquist RS, Koves TR, Muoio DM, MacIver NJ, Lamba JK, Pardee TS, McCall CM, Rizzieri DA, Wood KCCell metabolismLin KH, Xie A, Rutter JC, Ahn YR, Lloyd-Cowden JM, Nichols AG, Soderquist RS, Koves TR, Muoio DM, MacIver NJ, Lamba JK, Pardee TS, McCall CM, Rizzieri DA, Wood KC. Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity. Cell Metab. 2019 05 07; 29(5):1217-1231.e7.Cell Metab2019-02-14T00:00:002019Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity.30554278Kuhlman P, Isom S, Pardee TS, Burns C, Tawfik B, Lamar ZS, Powell BL, Klepin HDSupportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerKuhlman P, Isom S, Pardee TS, Burns C, Tawfik B, Lamar ZS, Powell BL, Klepin HD. Association between glycemic control, age, and outcomes among intensively treated patients with acute myeloid leukemia. Support Care Cancer. 2019 Aug; 27(8):2877-2884.Support Care Cancer2018-12-15T00:00:002018Association between glycemic control, age, and outcomes among intensively treated patients with acute myeloid leukemia.30962090Loh KP, Tooze JA, Nicklas BJ, Kritchevsky SB, Williamson JD, Ellis LR, Powell BL, Pardee TS, Goyal NG, Klepin HDJournal of geriatric oncologyLoh KP, Tooze JA, Nicklas BJ, Kritchevsky SB, Williamson JD, Ellis LR, Powell BL, Pardee TS, Goyal NG, Klepin HD. Inflammatory biomarkers, geriatric assessment, and treatment outcomes in acute myeloid leukemia. J Geriatr Oncol. 2020 04; 11(3):410-416.J Geriatr Oncol2019-04-05T00:00:002019Inflammatory biomarkers, geriatric assessment, and treatment outcomes in acute myeloid leukemia.24Assistant Professor2025-03-31NIHWATABE, KOUNOSUKE2020-04-01Translational Oncology Training ProgramT32CA247819Co-Principal InvestigatorInternal Medicine, General Internal MedicineInternal Medicine, Hematology & OncologyPathology, Comparative MedicinePediatrics, CardiologySurgery, OncologySurgery, TransplantUrologyhttp://www.wfirm.orgWFIRMAuthorship 145411Authorship 160141true1ProfessorProfessortrue1Assistant ProfessorAssistant Professor2ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessorAuthorship 227541Authorship 231742Authorship 29Authorship 31243Authorship 32511Authorship 329338Authorship 7984319339691Zuber J, Radtke I, Pardee TS, Zhao Z, Rappaport AR, Luo W, McCurrach ME, Yang MM, Dolan ME, Kogan SC, Downing JR, Lowe SWGenes & developmentZuber J, Radtke I, Pardee TS, Zhao Z, Rappaport AR, Luo W, McCurrach ME, Yang MM, Dolan ME, Kogan SC, Downing JR, Lowe SW. Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 2009 Apr 01; 23(7):877-89.Genes Dev2009-04-01T00:00:002009Mouse models of human AML accurately predict chemotherapy response.21288478Pardee TS, Zuber J, Lowe SWExperimental hematologyPardee TS, Zuber J, Lowe SW. Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner. Exp Hematol. 2011 Apr; 39(4):473-485.e4.Exp Hematol2011-02-01T00:00:002011Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner.22091497Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Ellis LR, Levitan D, Pardee TS, Isom S, Powell BLJournal of the American Geriatrics SocietyKlepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Ellis LR, Levitan D, Pardee TS, Isom S, Powell BL. The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. J Am Geriatr Soc. 2011 Oct; 59(10):1837-46.J Am Geriatr Soc2011-09-13T00:00:002011The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia.Authorship 343092Authorship 34411623081702Cook GJ, Pardee TSCancer metastasis reviewsCook GJ, Pardee TS. Animal models of leukemia: any closer to the real thing? Cancer Metastasis Rev. 2013 Jun; 32(1-2):63-76.Cancer Metastasis Rev2013-06-01T00:00:002013Animal models of leukemia: any closer to the real thing?23550038Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, Ellis LR, Powell BLBloodKlepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, Ellis LR, Powell BL. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013 May 23; 121(21):4287-94.Blood2013-04-02T00:00:002013Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia.AjayDharodAjay Dharod36.08959100000000-80.268599000000001452Dharod, AjayAssociate Professor12684381Pardee TS, Ghazy MA, Ponticelli ASEukaryotic cellPardee TS, Ghazy MA, Ponticelli AS. Yeast and Human RNA polymerase II elongation complexes: evidence for functional differences and postinitiation recruitment of factors. Eukaryot Cell. 2003 Apr; 2(2):318-27.Eukaryot Cell2003-04-01T00:00:002003Yeast and Human RNA polymerase II elongation complexes: evidence for functional differences and postinitiation recruitment of factors.Pardee TS. Hagag N. Singh B. Zamkoff K. Gladstone D.The Journal of Applied Research in Clinical and Experimental Therapeutics.Pardee TS. Hagag N. Singh B. Zamkoff K. Gladstone D. Effective CD34+ Stem Cell Mobilization with Low-dose Pegfilgrastim. The Journal of Applied Research in Clinical and Experimental Therapeutics. 2006; 6(3).2006-09-01T00:00:002006Effective CD34+ Stem Cell Mobilization with Low-dose Pegfilgrastim22362039Pardee TS, Gomes E, Jennings-Gee J, Caudell D, Gmeiner WHBloodPardee TS, Gomes E, Jennings-Gee J, Caudell D, Gmeiner WH. Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity. Blood. 2012 Apr 12; 119(15):3561-70.Blood2012-02-23T00:00:002012Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity.22905229Pardee TSPloS onePardee TS. Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim induction. PLoS One. 2012; 7(8):e43185.PLoS One2012-08-14T00:00:002012Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim induction.23085462Jennings-Gee J, Pardee TS, Gmeiner WHExperimental hematologyJennings-Gee J, Pardee TS, Gmeiner WH. Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity. Exp Hematol. 2013 Feb; 41(2):180-188.e4.Exp Hematol2012-10-17T00:00:002012Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity.23131583Puthiyaveetil AG, Reilly CM, Pardee TS, Caudell DLLeukemia researchPuthiyaveetil AG, Reilly CM, Pardee TS, Caudell DL. Non-homologous end joining mediated DNA repair is impaired in the NUP98-HOXD13 mouse model for myelodysplastic syndrome. Leuk Res. 2013 Jan; 37(1):112-6.Leuk Res2012-11-04T00:00:002012Non-homologous end joining mediated DNA repair is impaired in the NUP98-HOXD13 mouse model for myelodysplastic syndrome.D000971Procedures813980.768567Antineoplastic Combined Chemotherapy ProtocolsD000970Chemicals & Drugs1525320.69113Antineoplastic AgentsD017209Chemicals & DrugsPhysiology1253330.849044ApoptosisD015470Disorders361730.847964Leukemia, Myeloid, Acute